Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 11/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593522 | 0.92 | HDAC1 (0.46) | HDAC1F10GRM2F2 | |
| SCHEMBL14580203 | 0.89 | MAOB (0.53) | F10LMNAMAOAPTGS1MAOB | |
| SCHEMBL5384589 | 0.87 | HDAC1 (0.53) | HDAC1F10GRM2LMNAMAOA | |
| SCHEMBL14580196 | 0.83 | MAOA (0.46) | F10GRM2LMNAMAOAPTGS1 | |
| SCHEMBL5382057 | 0.82 | HDAC1 (0.55) | HDAC1GRM2ROCK2MAOAMAOB | |
| SCHEMBL5392289 | 0.81 | HDAC1 (0.46) | HDAC1GRM2ROCK2PKMSIGMAR1 | |
| SCHEMBL5382065 | 0.81 | HDAC1 (0.47) | HDAC1F10GRM2ROCK2 | |
| SCHEMBL14580205 | 0.80 | MAOB (0.57) | F10LMNAMAOAPTGS1MAOB | |
| SCHEMBL14597106 | 0.80 | GRM2 (0.54) | HDAC1F10GRM2ROCK2PKM | |
| SCHEMBL13428161 | 0.79 | GRM2 (0.53) | F10GRM2LMNAMAOAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7160912-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR.REDDY'S LABORATORIES LTD. (IN) | 2007-01-09 | — | — | US | disclosed |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-04 | — | — | US | disclosed |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | OXA1L, LSS, MRPL21 | HDAC1 148/4885F10 4007/4885GRM2 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.